Seasonal influenza vaccine formulation efforts struggle to keep up with viral antigenic variation. Two studies now report engineered or naturally occurring human antibodies targeting the influenza hemagglutinin (HA) stem, with exceptional neutralizing breadth (Joyce et al., 2016; Kallewaard et al., 2016) . Antibodies with similar structural features are elicited in multiple subjects, suggesting that modified vaccine regimens could provide broad protection.
To paraphrase Jane Austen, it is a truth universally acknowledged that an individual in possession of a good broadly neutralizing antibody response to a virus must be in want of characterization. The human immune response to influenza has been no exception. The tools of monoclonal antibody (mAb) characterization from single B cells, and tracking of the clonal evolution of B cell populations by high-throughput antibody sequencing, are providing an increasingly high-resolution map of human immunity to a range of pathogens and vaccines (Andrews et al., 2015; Liao et al., 2013) . Influenza is a significant global health challenge with millions of infections and up to half a million deaths globally each year, despite efforts to increase vaccination in at-risk populations. Influenza virus is a challenging target for antibodies because of antigenic drift and shift, genetic processes that produce ongoing and occasionally abrupt antigenic changes. Antibodies elicited by seasonal influenza vaccination tend to target the rapidly mutating globular head of hemagglutinin (HA), facilitating viral escape from responses raised to other viral strains (Krammer and Palese, 2013) . Broadly neutralizing antibodies (bnAbs) directed against the structurally conserved HA stem could provide more enduring protection, and examples of these have been isolated (Krammer and Palese, 2013) . These antibodies have revealed some stereotyped features, such as IGHV1-69 usage in multiple subjects (Corti et al., 2010) . These responses in vivo in humans, however, seem to arise from low-frequency clones, are present at lower titers than head-specific antibodies, and have neutralization breadth usually limited to homologous subtypes. bnAbs with neutralizing breadth covering both influenza A group 1 and group 2 subtypes would be far more valuable, if they could be reliably stimulated by new vaccine regimens. Such antibodies have only rarely been observed in responses to vaccination or infection (Corti et al., 2011) . In this issue, Joyce et al. (2016) and Kallewaard et al. (2016) apply distinct approaches to obtain bnAbs with breadth against both influenza A group 1 and group 2 subtypes. Joyce et al. (2016) study stereotyped or ''convergent'' antibody responses across multiple human donors after H5 hemagglutinin primed and repeatedly boosted influenza vaccination, and they define new multi-donor bnAb classes ( Figure 1 ). Kallewaard et al. (2016) engineer and improve a single-subject-derived mAb to obtain unprecedented neutralization breadth. The identification of convergent classes of antibodies capable of neutralizing both influenza A group 1 and group 2 subtypes builds upon a growing body of literature showing that the diverse antibody-mediated responses of different humans can converge on similar solutions to complex antigen targeting (Jackson et al., 2014; Trü ck et al., 2015) . The bnAb developed by Kallewaard et al. (2016) shows structural similarities to one of the bnAb classes identified by Joyce et al. (2016) . Kallewaard's engineered MEDI8852 bnAb reacts to representatives of all influenza A subtypes from the last 80 years and is derived from a naturally occurring antibody whose heavy chain uses IGHV6-1, IGHD3-3, and IGHJ3 gene segments with low levels of somatic hypermutation.
This bnAb interacts with a highly conserved epitope in the hydrophobic groove in the fusion domain plus a large portion of the fusion peptide (Kallewaard et al., 2016) . Similarly, one of the convergent antibody classes isolated from three subjects by Joyce et al. (2016) also utilizes IGHV6-1 and IGHD3-3, binds the HA stem but avoids the conserved HA1 glycans of both group 1 and group 2 subtypes, and uses a somatically mutated CDR H3 residue to insert into the Trp21 pocket in the hydrophobic groove of HA2. Two additional convergent bnAb classes identified by Joyce et al. (2016) , both using IGHV1-18, bind the HA fusion peptide-helix A region suggesting this region is a recurrent target for bnAbs.
These two studies contribute to ongoing efforts to understand the threedimensional structural features and the underlying primary antibody sequences used to recognize viruses that can alter many, but not all, of their epitopes. They add to a growing list of such structurally conserved vulnerable targets for neutralization in influenza, akin to those for HIV (Liao et al., 2013) , and demonstrate that shared antibody structural motifs for binding viral epitopes are formed in different individuals, despite the vast diversity of antibody repertoires. Analogous convergent antibodies contribute to human antibody responses to many, if not all, pathogens (Jackson et al., 2014; Trü ck et al., 2015) , but not all convergent antibodies are neutralizing or otherwise protective. Structurally constrained pathogen epitopes required for survival may be under selection so that they are not highly antigenic and may only be accessible to antibodies that are difficult for humans to elicit, for example, because they are autoreactive or polyreactive and trigger poorly defined human B cell tolerance mechanisms (Liao et al., 2013) .
It is less clear how much of any individual's actual serum antibody response to influenza vaccination is composed of such bnAbs or whether optimized vaccination regimens could elicit them at high enough titers to be functionally protective. Ongoing antibody proteomic research with improved mass spectrometry methods may help to address these key questions, particularly if applied in clinical trials in which protection from infection can be measured (Wine et al., 2013) . What do these studies teach us about immunogen design or selection?
The pragmatic goal of better vaccine efficacy against divergent viral strains could be served equally well by eliciting rare antibodies with extreme breadth or a handful of antibody lineages with complementary partial breadth. The success of each scenario could depend on the titers reached and the durability of the response. Evaluating the feasibility of these goals will likely require testing vaccine regimens using heterologous antigens that are more divergent than those in current vaccine formulations and assessing antigenic combinations, the ordering of antigen administration, and the effects of adjuvants, while analyzing the kinds of antibodies that are stimulated in each case. Of course, very potent bnAbs are potential passive immunoprotective or therapeutic drug candidates that could be particularly helpful in populations with compromised immune function, such as the very elderly.
The combination of structural analysis and extensive sequence characterization of antibody repertoires, married with functional testing of mAbs, has greatly empowered the analysis of human B cell responses to real pathogens and vaccines. These new studies underscore the value of taking cues from the structural problem solving of the immune system, when designing new candidate therapeutics, and they add to the evidence that there are predictable features of human adaptive immune responses that can be accessed by properly designed vaccine regimens to achieve greater efficacy. After exposure to influenza vaccines or viral infections, each individual produces a mixture of different antibodies specific for a variety of epitopes on the hemagglutinin protein (indicated by antibody color and epitope color on the hemagglutinin trimer; epitopes are colored on only one of the HA trimers for clarity). Antibodies that bind to the highly variable head region are most often strain-specific, while antibodies that bind the more conserved stalk region have the potential to neutralize a wider variety of strains. Rare stalkbinding antibodies that neutralize influenza strains spanning the major antigenic group 1 and group 2 categories have been previously reported. Joyce et al. (2016) now identify several categories of such broadly neutralizing antibodies (indicated with circles) that also show structural convergence between different donors (i.e., very similar antibodies are elicited in different individuals, despite the huge diversity of antibody repertoires). Kallewaard et al. (2016) describe an engineered antibody with particularly extensive neutralizing breadth, which shares structural similarity with one of the antibody classes in Joyce et al. (2016) and binds to a similar epitope.
